Expectations trend
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsNASDAQInformation TechnologyInformation Technology ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for DAIC yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Effective management of capital and financial obligations | A primary condition in CID HOLDCO INC's published investment case. The stated target is Maintain controlled capital allocation and reduce financial risk. | Under Pressure | New large financial obligations or equity sales increase risk | Qualitative: New equity sales & loan termination Unregistered equity sales and termination of a material definitive agreement regarding executive loans reported in Oct 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
DAIC is a speculative growth and recovery case, not a proven durable compounder. The thesis is in a watch state, with volatile management, weak recent financial performance, and high risk.
The valuation signal says DAIC is cheap versus peers, but confidence in that comparison is low. The valuation score recently fell, while the supplied evidence does not show a clear measure of what expectations the market has already priced in.
Near term, the reported 2026-Q2 revenue was $12,398 and operating income was -$3,029,729, while management’s stated 2026 revenue guidance was $6 million to $7.5 million. Management has stated priorities to integrate Envoy and grow its business, but the supplied results do not show post-acquisition operating progress or isolate Envoy revenue. Continued-listing compliance remains a risk, with transfer and other conditions still outstanding.
The multi-year view hinges on whether DAIC can demonstrate Envoy integration, revenue growth, and a broader commercial footprint in measurable results. Near term, a guidance cut would be a negative signal, while Fed rate cuts or stabilization among sector bellwethers could support the technology backdrop. The October 13 delisting-related notice adds uncertainty, and the supplied evidence gives limited detail on its resolution.
Over the next 1 to 3 years, DAIC’s thesis depends on turning stated acquisition and growth priorities into evidence of operating progress while addressing listing conditions. The evidence remains thin and the risk is high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful implementation of reverse stock split | A supporting condition in CID HOLDCO INC's published investment case. The stated target is Complete reverse stock split as planned. | Improving | Reverse split is delayed or cancelled | Nasdaq compliance exception granted vs target of completed split Nasdaq Hearings Panel granted request for continued listing and exception to complete compliance plan. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue reaches about $6.75 million in 2026 | Revenue guidance targets about $6.75 million for 2026. | Intact | Revenue falls below $6 million in FY26 | Revenue: $12,398 FY2026-Q2; GAAP. Published target: ~$6.75 million. Annual target cannot be compared with a quarterly or TTM observation. Sep 25, 202612,398 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.